New combo shows promise for tough liver and bile duct cancers

NCT ID NCT03092895

First seen Feb 01, 2026 · Last updated May 13, 2026 · Updated 15 times

Summary

This study tested a new combination treatment for people with advanced liver cancer or bile duct cancer. It used an immunotherapy drug (SHR-1210) plus either a targeted therapy (apatinib) or chemotherapy. The goal was to see if the combination was safe and could shrink tumors. 157 patients took part, and the results help guide future treatment options.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • 81 Hospital Nanjing

    Nanjing, Jiangsu, 210002, China

  • Cancer Hospital of Henan province

    Zhengzhou, Henan, 450008, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, 200032, China

  • Hunan Cancer Hospital

    Hunan, Changsha, 410000, China

  • The First Affiliated Hospital of Nanchang University

    Jiangxi, Nanchang, 330006, China

  • The Second Affiliated Hospital Of Anhui Medical University

    Hefei, Anhui, 230000, China

  • Zhongshan Hospital

    Shanghai, Shanghai Municipality, 200003, China

Conditions

Explore the condition pages connected to this study.